Biofrontera Inc. will report 2024 financial results on March 21, 2025, and host a conference call that same day.
Quiver AI Summary
Biofrontera Inc., a biopharmaceutical company focused on dermatological products, announced that it will release its financial results for the three and twelve months ending December 31, 2024, on March 21, 2025, before the market opens. Following the release, the company will host a conference call at 10:00 AM Eastern Time on the same day. Biofrontera specializes in the development and commercialization of its product Ameluz®, used in photodynamic therapy (PDT) for treating actinic keratosis and other skin conditions. The company is also conducting clinical trials to explore the use of its products for non-melanoma skin cancers and severe acne. Further information can be found on their website and social media channels.
Potential Positives
- Announcement of financial results provides transparency and demonstrates accountability to investors.
- Conference call scheduled to discuss financial results and business updates enhances communication with stakeholders.
- Focus on dermatological products, including innovative treatments for skin conditions, positions the company in a specialized and potentially lucrative market.
Potential Negatives
- The press release does not provide any specific details regarding the expected financial results, leaving stakeholders uncertain about the company's performance.
- The absence of any updates on product development or clinical trial outcomes may signal a lack of progress, which could negatively impact investor confidence.
- Releasing financial results and holding a conference call on the same day may limit the attention and detail given to the results, potentially leading to misunderstandings or missed opportunities for clarity among analysts and investors.
FAQ
When will Biofrontera Inc. release its financial results?
Biofrontera Inc. will release its financial results on March 21, 2025, before the market opens.
What time is the conference call for the financial results?
The conference call will take place at 10:00 AM Eastern Time on March 21, 2025.
How can I listen to the Biofrontera conference call?
You can listen to the conference call by dialing 1-877-877-1275 (U.S.) or 1-412-858-5202 (international).
What products does Biofrontera specialize in?
Biofrontera specializes in dermatological products, focusing on treatments like Ameluz® and PDT for skin lesions.
Where can I find more information about Biofrontera Inc.?
More information can be found on Biofrontera's website at www.biofrontera-us.com, as well as on their LinkedIn and X pages.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time.
Conference Call and Webcast Information
| Date | Friday, March 21, 2025 |
| Time | 10:00 AM Eastern Time |
| Dial In Numbers |
1-877-877-1275 (U.S.)
1-412-858-5202 (international) |
| Webcast | Fourth Quarter and FY 2024 Financial Results and Business Update Conference Call |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X .
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
[email protected]
SOURCE: Biofrontera Inc.
